Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To support development of anticoagulant reversing agents
Subscribe to our email newsletter
PolyMedix has declared that it has received a phase-II Small Business Innovation Research (SBIR) grant in the amount of $923,080. The fund will be disbursed over a period of two years, to support the development of anticoagulant reversing agents, compounds PolyMedix calls heptagonists.
The National Institutes of Health (NIH) has sponsored the grant for the development of LMWHs. The phase-II SBIR grant follows successful completion of a phase-I SBIR grant in the amount of $100,000, received by PolyMedix in September 2007 to support the work. The new grant is expected to support four scientific staff at PolyMedix.
The primary goal of the work funded by this grant will be to discover lead compounds suitable for development as antagonists to the anticoagulation activities of low molecular weight heparins (LMWHs), such as Lovenox (enoxaparin) and fondaparinux.
This grant represents the eighth outside supported funding, in the form of a grant or research contract, received by PolyMedix.